

# Investor Presentation February 2020



# **Company Overview**



■ Manufacturer of consumables and equipment for mining and industry, for X-Ray Fluorescence (XRF) analysis — a powerful long-established analytical technique, vital to the discovery, evaluation, qualification and production of most metals and control of material manufacturing processes

# X-Ray Flux and chemicals





# Platinum Labware and Precision Platinum Products






# Specialised furnaces and laboratory equipment



# **The XRF Analysis Process**





The glass disk is presented into an x-ray spectrometer for analysis

The sample dust is then fused into a glass bead using **XRF Scientific's products** 

## **Our Products**



**Products** 

Service

**Applications Support** 

## Laboratory











#### Sample sources:

- Production
- Shipping
- Exploration

### **Industry**



#### Materials:

- Cement
- Steel
- Glass
- Ceramics
- Research
- Education

#### Minerals:

- Iron ore
- Nickel
- Copper
- Aluminium
- Bauxite
- Manganese
- Uranium
- Lithium
- Mineral sands
- Commercial labs

# **Half Year Results – Overview**



	Half Year Results			ı	Full Year Results	s
(\$m)	1H20	1H19	Change	2019	2018	2017
Sales revenue	15.7	15.0	5%	29.0	24.2	21.5
EBIT	2.3	1.7	40%	3.2	1.6	1.0
Profit before tax	2.3	1.6	41%	3.2	1.5	1.0
Net profit after tax	1.6	1.1	51%	2.1	1.0	0.8
Earnings per share (cents)	1.2	0.8	51%	1.6	0.8	0.6
Weighted average no. of shares	133,825,803	133,825,803		133,825,803	133,825,803	133,825,803
Dividends (cents per share)	0.0	0.0		1.0	0.30	0.24
Dividend payout ratio	-	-		63%	39%	40%

## **Balance Sheet**



(\$m)	1H20	2H19	Change
Cash and cash equivalents	1.6	3.2	(50%)
Trade and other receivables	5.0	4.1	23%
Inventories	9.4	8.7	8%
Other assets	0.4	0.4	0%
Property, plant and equipment	8.3	8.4	(1%)
PPE lease asset*	1.0	0.0	100%
Intangible assets	16.0	16.0	0%
Deferred tax asset	0.9	0.9	2%
Total assets	42.6	41.7	2%
Trade and payables			
- platinum loan provisions	2.2	2.0	14%
- other items	2.4	3.0	(21%)
Debt (short term)	0.9	0.7	26%
Debt (long-term)	1.4	1.6	(11%)
Current lease liabilities*	0.4	0.0	100%
Non-current lease liabilities*	0.6	0.0	100%
Income tax liability	0.4	0.4	(7%)
Deferred tax liability	0.2	0.2	(2%)
Total liabilities	8.5	7.9	7%
Total equity	34.1	33.8	1%

- \*Arises from adoption of AASB 16 since 1 July 2019. See Note 3 of Interim Financial Statement for further details
- Platinum loan quantities remain the same and were adjusted for market prices at rollover dates through the period. Corresponding increase made to platinum asset in Inventories asset

### **Cash Flow Statements**



(\$m)	1H20	2H19	1H19
Net cash inflow from operating activities	0.4	2.6	1.3
Net cash (outflow) from investing activities	(0.5)	(0.4)	(0.2)
Net cash inflow/(outflow) from financing activities	(1.5)	(0.2)	(0.3)
Cash at start of period	3.2	1.2	0.4
Net increase/(decrease) in cash	(1.6)	2.0	0.8
Cash at end of period	1.6	3.2	1.2

#### **Highlights:**


- \$1.3m in dividends paid during the half vs \$0.4m in PCP (1H19)
- Operating cash flow affected by strong sales activity towards end of half increasing debtors by \$950 to \$5m. Trade and other payables were also down by \$0.5m compared to 30 June
- Cash position has developed to \$2.7m at 19 February 2020

## **Consumables**



(\$m)	1H20	2H19	1H19
Sales revenue	4.8	3.6	4.4
Change in % *	34%	(18%)	29%
NPBT	1.3	1.0	1.2
Change in % *	38%	(18%)	116%
Margin %	28%	27%	27%

<sup>\*</sup> Compared to immediately prior half-year period



#### Overview for 1H20:

- Revenue up 34% on 2H19
- NPBT up 38% on 2H19
- Conditions buoyant in the mining sector across production and exploration
- New customers acquired during FY19 now delivering regular revenue


### **Precious Metals**



(\$m)	1H20	2H19	1H19
Sales revenue	7.3	6.7	6.4
Change in % *	9%	4%	10%

NPBT	0.7	0.5	0.4
Change in % *	49%	6%	252%
Margin %	10%	7%	7%

<sup>\*</sup> Compared to immediately prior half-year period



2H16 1H17 2H17 1H18 2H18 1H19 2H19 1H20

**Net Profit Before Tax (\$'000)** 

1H16

#### Overview for 1H20:

- Revenue up 9% on 2H19
- NPBT up 49% on 2H19
- Revenue from Germany office \$1.6m vs \$1.1m in PCP (1H19). Continued revenue growth expected in second half with new customers coming online
- Technical breakthroughs made at Melbourne factory, expanding industrial and semi-finished product lines – broadening the portfolio and bringing capability in-house


# **Capital Equipment**



(\$m)	1H20	2H19	1H19
Sales revenue	4.3	4.3	4.9
Change in % *	(1%)	(13%)	28%

NPBT	0.4	0.3	0.4
Change in % *	44%	(25%)	221%
Margin %	9%	6%	7%

<sup>\*</sup> Compared to immediately prior half-year period



**Net Profit Before Tax (\$'000)** 

#### Overview for 1H20:

- Revenue flat on 2H19
- NPBT up 44% on 2H19
- Margin improvement from increased proportion of end user sales / product mix sold and reduction in operating costs
- Two new machines under development for release within 2020 calendar year

## Our plans for 2020



- Continuing our expansion in the Precious Metals Division, with growth in profits expected to continue
- Continue with geographical expansion initiatives
- Acquire a greater market share for Consumable products
- Planning to release two new capital equipment products during the 2020 calendar year
- Continue to pursue M&A opportunities. Our targets are complementary manufacturing companies, in the laboratory supply or precious metals sectors
- Implement a Dividend Reinvestment Plan
- Work to improve our scale/market cap and the share price

# **Contact Information**

Tel: (08) 9244 0600

86 Guthrie St. Osborne Park WA

Vance Stazzonelli – CEO vance@xrfscientific.com

### **Disclaimer**



#### No responsibility for contents of Investor Presentation

- •To the maximum extent permitted by law, XRF Scientific Limited and representatives:
- •make no representation, warranty or undertaking, express or implied, as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient;
- •accept no responsibility or liability as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient; and
- •accept no responsibility for any errors or omissions from this Investor Presentation whether arising out of negligence or otherwise.

#### Accuracy of projections and forecasts

•This Investor Presentation includes certain statements, opinions, estimates, projections and forward looking statements with respect to the expected future performance of XRF Scientific Limited. These statements are based on, and are made subject to, certain assumptions which may not prove to be correct or appropriate. Actual results may be materially affected by changes in economic and other circumstances which may be beyond the control of XRF Scientific Limited. Except to the extent implied by law, no representations or warranties are made by XRF Scientific Limited, its advisers or representatives as to the validity, certainty or completeness of any of the assumptions or the accuracy or completeness of the forward looking statements or that any such statement should or will be achieved. The forward looking statements should not be relied on as an indication of future value or for any other purpose.

#### No offer to sell or invitation to buy

•This Investor Presentation does not, and should not be considered to, constitute or form part of any offer to sell, or solicitation of an offer to buy, any shares in XRF Scientific Limited, and no part of this Investor Presentation forms the basis of any contract or commitment whatsoever with any person.

This Investor Presentation does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not permitted under applicable law. Distribution of this Investor Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients must inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Neither XRF Scientific Limited, its advisers or representatives accept any liability to any person in relation to the distribution or possession of this Investor Presentation from or in any jurisdiction.